CasNo.1620576-64-8,AZD-8835,1-(4-(5-(5-amino-6-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1H-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one(1620576-64-8) Suppliers

0	Negotiable

Min.Order :0
Purity: 95%

Keywords

1-[4-[5-[5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl]-1-ethyl-1,2,4-triazol-3-yl]piperidin-1-yl]-3-hydroxypropan-1-one<br/>AZD-8835<br/>1620576-64-8<br/>GTPL8915<br/>SCHEMBL15877923<...

Quick Details

Appearance:Light yellow to yellow Solid
Application:For research use only.
PackAge:
ProductionCapacity:
Storage:Store in a cool and dry place and at 0 - 4°C for short term (days to weeks) or -33°C for long term (months to years).
Transportation:

Superiority:

We provide customized and high-quality AZD-8835 product for your project.

Details:

AZD-8835 was selected as a clinical candidate for the treatment of PIK3CA-dependent cancers and is currently in phase I clinical trials. It is an orally bioavailable inhibitor of the class I (PI3K) catalytic subunit alpha (PIK3CA).
IC50: PI3Kδ= 5.7 nM, PI